Compound class:
Peptide
Comment: Blisibimod is a peptibody fusion containing four BAFF binding domains fused to a human Fc domain. By sequestering circulating BAFF ligand, it acts as a functional antagonist of BAFF interaction with the TACI receptor on B cells.
Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for blisibimod is claimed in Amgen's patent WO2002092620 [5]. |
Classification  |
|
| Compound class | Peptide |
| International Nonproprietary Names |
|
| INN number | INN |
| 9583 | blisibimod |
| Synonyms |
|
| A-623 | AGP3 peptibody [5] | AMG 623 | Fc-Agp-3 [1] | |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 413 |
| Other databases | |
| GtoPdb PubChem SID | 336446905 |
| Search PubMed clinical trials | blisibimod |
| Search PubMed titles | blisibimod |
| Search PubMed titles/abstracts | blisibimod |
